MONIQUE BARCONEY: Open Payments
NPI 1811961311 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,070 in 82 payments from 23 companies in 2025. Trend: 2023 $1,540 · 2024 $2,392 · 2025 $2,070
Food & beverage: $2,070
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $272 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $227 |
| Amgen Inc. | 8 | $201 |
| ABBVIE INC. | 16 | $177 |
| Merck Sharp & Dohme LLC | 8 | $172 |
| Novo Nordisk Inc | 2 | $143 |
| ViiV Healthcare Company | 1 | $125 |
| UCB, Inc. | 4 | $113 |
| Teva Pharmaceuticals USA, Inc. | 5 | $102 |
| GlaxoSmithKline, LLC. | 4 | $89 |
Products named: CAPLYTA, AIRSUPRA, PIFELTRO, VRAYLAR, Ozempic, REPATHA, OTEZLA, TRELEGY ELLIPTA.
Industry payments across LA — which companies pay providers there.
